$1.94
3.96% yesterday
Nasdaq, Jul 29, 10:00 pm CET
ISIN
CH0523961370
Symbol
NLSP

NLS Pharmaceutics Ltd Stock price

$1.94
-0.96 33.10% 1M
-0.02 1.02% 6M
-0.17 8.06% YTD
-7.41 79.26% 1Y
-12.85 86.88% 3Y
-113.66 98.32% 5Y
-113.66 98.32% 10Y
-113.66 98.32% 20Y
Nasdaq, Closing price Tue, Jul 29 2025
-0.08 3.96%
ISIN
CH0523961370
Symbol
NLSP
Industry

Key metrics

Basic
Market capitalization
$7.3m
Enterprise Value
$5.6m
Net debt
positive
Cash
$1.7m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
63.0%
Return on Equity
-288.5%
ROCE
-259.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-3.6m | -
EBIT
$-3.6m | $-27.2m
Net Income
$-4.1m | $-1.5m
Free Cash Flow
$-4.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
69.2% | -
EBIT
69.2% | -648.3%
Net Income
66.6% | 64.3%
Free Cash Flow
55.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.0
FCF per Share
$-1.4
Short interest
3.4%
Employees
7
Rev per Employee
$0.0
Show more

Is NLS Pharmaceutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

NLS Pharmaceutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a NLS Pharmaceutics Ltd forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a NLS Pharmaceutics Ltd forecast:

Hold
50%
Sell
50%

Financial data from NLS Pharmaceutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.21 3.21
46% 46%
-
- Research and Development Expense 0.42 0.42
93% 93%
-
-3.63 -3.63
69% 69%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.64 -3.64
69% 69%
-
Net Profit -4.06 -4.06
67% 67%
-

In millions USD.

Don't miss a Thing! We will send you all news about NLS Pharmaceutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NLS Pharmaceutics Ltd Stock News

Neutral
PRNewsWire
13 days ago
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH , July 17, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today announced that the Israel-U.S....
Neutral
PRNewsWire
30 days ago
Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its ...
Neutral
PRNewsWire
about one month ago
ZURICH , June 16, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd.  (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.
More NLS Pharmaceutics Ltd News

Company Profile

NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder(ADHD). The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.

Head office Switzerland
CEO Alexander Zwyer
Employees 7
Founded 2015
Website nlspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today